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Abstract  1 
We assessed the cost-effectiveness of offering catch-up vaccination with Bexsero against 2 
meningococcal disease to children too old to receive the vaccine under the recently 3 
introduced infant programme.  Offering catch-up vaccination to increasingly older children is 4 
less economically attractive because of declining disease burden.  We estimate catch-up 5 
vaccination of 1 year old children could be cost-effective, incremental on the infant 6 
programme with a vaccine price of ≤£8 per dose.  Extending vaccination to 2 year olds could 7 
only be cost-effective (incremental on infant and 1 year old catch-up) with a vaccine price of 8 
≤£3 per dose and was not cost-effective in sensitivity analyses with more conservative 9 
vaccine assumptions.  Extending catch-up further to 3-4 year olds was not cost-effective.  10 
Employing the current criteria for assessing vaccines, our models suggest that even with low 11 
vaccine prices only catch-up vaccination in 1 year old children could be cost-effective, when 12 
considered incrementally on the infant programme. 13 
 14 
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Introduction 1 
In September 2015 the UK became the first country in the world to routinely offer to infants a 2 
vaccine (Bexsero) against MenB disease at 2, 4 and 12 months of age.  The decision to 3 
immunise infants was made by the Joint Committee on Vaccination and Immunisation 4 
(JCVI), based on evidence that this age group are the most at risk of invasive disease and 5 
that immunising this group could be cost-effective if the vaccine was procured at a low 6 
price1.  7 
 8 
In spring 2016 the largest health petition in UK history was received by parliament, calling for 9 
vaccination against meningococcal group B disease (MenB) for all children up the age of 11 10 
years2.  As part of the original vaccine decision making process, there were several 11 
iterations of mathematical and economic models, which considered many different 12 
vaccination strategies, including catch-up strategies targeting pre-school (1-4 years) or 13 
school-aged (5-17 years) children3 4. One of the key uncertainties is whether Bexsero can 14 
prevent transmission of the meningococcus and induce herd protection5.  Assuming that the 15 
vaccine provides direct protection only, our previous models have shown that catch-up 16 
vaccination was unlikely to be cost-effective, and therefore could not be recommended by 17 
JCVI.   18 
 19 
The aim of this modelling study was to further investigate the cost-effectiveness of different 20 
catch-up options, focusing not on children under 11 years, but on the birth cohorts after 21 
infancy who experience the greatest disease burden, i.e. 1, 2 and 3-4 year olds. 22 
 23 
Methods 24 
We adapted the transmission dynamic mathematical and economic model used to inform the 25 
infant vaccination JCVI decision3 to consider additional catch-up vaccination options.  We 26 
modelled vaccination as a two dose schedule delivered 1 month apart in catch-up cohorts 27 
(vaccine uptake in catch-up cohorts was assumed to be the same as for the MenC vaccine 28 
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campaign6).  In the base case we assumed the vaccine covered 88%7 of circulating 1 
meningococcal strains with a 30% vaccine efficacy against carriage acquisition5 and 95% 2 
vaccine efficacy against disease8 9. 3 
 4 
We used the same parameter values in the model as considered previously3, except for the 5 
price for the vaccine delivery cost.  The fee given to GPs for administering vaccines and 6 
immunisations increased from £7.50 to £9.80 per dose from 1 April 201610.  The model 7 
includes costs of: acute hospital care and initial follow-up appointments, public health 8 
response, long term support for survivors with sequelae, and litigation claims against the 9 
NHS.  Disease incidence and case fatality estimates were drawn from Hospital Episode 10 
Statistics data over a seven year (2005/06-2011/12) period to allow for potential future 11 
increases in disease; in a historical context the UK is currently experiencing low disease 12 
incidence.  Vaccine delivery costs are modelled separately from the cost of the vaccine and 13 
costs of adverse reactions are also considered.  The benefits of vaccination are captured 14 
through gains in Quality Adjusted Life Years (QALY) through reducing disease cases, 15 
sequelae and death; QALY gains in family and network members were considered in 16 
sensitivity analyses.  Previously the JCVI specified a QALY adjustment factor of x3 should 17 
be applied in the model for long-term sequelae due to concerns surrounding the ability of 18 
current tools to adequately capture quality of life losses due to meningococcal disease.  This 19 
adjustment factor was retained in this iteration of the model. 20 
 21 
The cost-effectiveness of catch-up vaccination was considered incrementally on the existing 22 
routine infant programme; we did not consider catch-up vaccination beyond 4 year olds 23 
because our previous work (data not shown3) had indicated this would not be cost-effective.  24 
Future costs and benefits were discounted at 3.5% in the base case and analyses were 25 
undertaken from the NHS and personal and social services perspective.  Strategies were 26 
deemed cost-effective if the discounted cost per QALY gained was <£20,000 for the base 27 
case.  For consistency with the routine infant immunisation decision by JCVI we considered 28 
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a conservative scenario assuming 66% strain coverage for the vaccine and no herd effects 1 
(no vaccine efficacy against carriage acquisition); this was deemed cost-effective if the 2 
discounted cost per QALY gained was <£30,00011 12.  We also assessed the effect of using 3 
1.5% discounting for cost and benefits, including family and network QALYs, assuming a 4 
lower incidence and returning to the previous vaccine delivery cost of £7.50 per dose. 5 
 6 
Results 7 
In the base case model, catch-up vaccination of 1 year old children (83.8% uptake) with 8 
Bexsero could be considered cost-effective, incremental on the existent routine infant 9 
programme, if the vaccine could be procured at a low vaccine price, estimated at ≤£8 per 10 
dose with a threshold of £20,000 per QALY gained (Table 1).  Extending the catch-up to 11 
include 2 year olds (75.6% uptake) was less economically attractive, driven by the fact that 12 
disease incidence in 2 year olds is lower than in 1 year old children; in the absence of 13 
vaccination the model assumes 359 cases in infants (annual incidence 52.9/100,000 14 
persons, 0 year olds), 193 cases in 1 year olds (28.5/100,000) and 111 cases in 2 year olds 15 
(16.4/100,000).  We estimated that catch-up vaccination in 2 year olds, incremental on the 16 
routine infant programme and 1 year old catch-up, could only be cost-effective if the vaccine 17 
were priced £3 per dose or less.  It was not possible to find a positive vaccine price when 18 
extending catch-up further to 3 and 4 year olds (annual incidence 11.2 and 8.4/100,000 19 
respectively; 75.6% vaccine uptake in both year groups), and since disease incidence falls  20 
further after this age, the same applies up to age 11 years. 21 
 22 
Reducing the discounting for costs and benefits from 3.5% to 1.5% improves the incremental 23 
cost-effectiveness ratio and increases the threshold vaccine price. In this scenario catch-up 24 
vaccination in 1 year olds could be cost-effective at £20 per dose, incremental on the infant 25 
programme, extending this to 2 year olds and then to 3-4 year olds could be incrementally 26 
cost-effective at £12 and £6 per dose respectively. 27 
 28 
Page 6 of 13 
24 October 2016 
If the previous vaccine delivery cost of £7.50 per dose is used instead of the new £9.80 fee, 1 
the estimated ‘cost-effective’ vaccine prices for 1 and 2 year old catch-up are increased by 2 
£2.30 a dose and extending catch-up to 3-4 year olds could then be deemed cost-effective 3 
at a vaccine price ≤£2 per dose.   4 
 5 
Disease incidence naturally varies over time even in the absence of intervention against 6 
MenB disease.  The base case model uses incidence over a seven year period to allow for 7 
such future changes in disease, but this is higher than the low burden currently experienced.  8 
Reducing the modelled number of annual cases of disease by a third, to more closely 9 
resemble the incidence experienced currently, rules out many catch-up strategies from an 10 
economic perspective.  Only 1 year old catch-up could be cost-effective in this scenario and 11 
only with a vaccine price of ≤£1 per dose. 12 
 13 
In the conservative scenario with 66% vaccine strain coverage and no herd effects (all other 14 
parameters at base case values), using a threshold of £30,000 per QALY gained, only catch-15 
up vaccination in 1 year old children could be considered cost-effective and only with a very 16 
low vaccine price of ≤£2 per dose (Table 2).  However, if family and network QALYs were 17 
included this could be increased to £6 per dose.  Under extremely conservative assumptions 18 
(lower disease incidence, 66% strain coverage, no herd effects or litigation costs) none of 19 
the catch-up policies could be considered cost-effective with 3.5% discounting.  Conversely 20 
using highly favourable assumptions (91% strain coverage, 60% vaccine efficacy against 21 
carriage, including litigation costs and quality of life losses in family and network members, 22 
with 1.5% discounting) catch-up vaccination of 1, 2 and 3 to 4 year olds could be 23 
incrementally cost-effective at £35, £24 and £18 per dose respectively with a willingness to 24 
pay of £20,000 per QALY gained. 25 
 26 
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Discussion 1 
Our model estimates that offering Bexsero to 1 year old children in a catch-up campaign 2 
could be cost-effective at £8 per dose with a willingness to pay of £20,000 per QALY.  3 
Providing catch-up vaccination to older birth cohorts is less economically attractive due to a 4 
decreasing disease burden, and even extending vaccine to 2 year olds could not be 5 
considered cost-effective.     6 
 7 
A strength of this work is that it builds upon a previously independently reviewed model 8 
which was used to inform the infant recommendation for the use of Bexsero in the UK11.  9 
There remains, however a considerable degree of uncertainty around many of the model 10 
parameters and whilst surveillance data will help to reduce some of this uncertainty, it is still 11 
too early in the programme to be able to revise any of the assumptions, for example of 12 
vaccine effectiveness.  To our knowledge this is the first study to consider the cost-13 
effectiveness of extending catch-up vaccination in individual birth cohorts after infancy.  14 
Previous models have either considered routine programmes only13 14 or catch-up in a 15 
number of birth cohorts combined3 15 16. 16 
 17 
Although our models suggest catch-up vaccination in 1 year olds could be cost-effective, it 18 
may be challenging to achieve this in practice.  Our base case models assume the vaccine 19 
has some ability to disrupt transmission and carriage although the evidence for this is limited 20 
at present5.  It is thought that carriage prevalence is low in young children17, thus the 21 
potential herd effects generated through vaccinating this age group may not be large. 22 
However, excluding any effect on carriage reduces the already low cost-effective vaccine 23 
price.  The price procured per dose of vaccine for the infant programme is confidential.  Thus 24 
while the price per dose for 1 year old catch-up appears similar to that estimated for the 25 
infant programme, if additional factors had to be included for a vaccine price to be agreed for 26 
the infant programme (such as the removal of an infant meningococcal C conjugate vaccine 27 
dose from the current schedule11), procurement of doses for catch-up may not be possible at 28 
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the prices we have suggested.  Changes have also recently been made to the vaccine 1 
delivery cost and while there is currently no scope for reverting to the previous cost, our 2 
findings highlight that vaccine recommendation decisions can be affected by the 3 
administration fee.  The window of opportunity to vaccinate these individuals is also limited.  4 
Babies born after 1 May 2015 are already eligible for vaccination through the NHS infant 5 
schedule, thus the cohort of toddlers who are aged 1 and who have not been vaccinated is 6 
reducing.  Given the seasonal nature of meningococcal disease any catch-up vaccination 7 
would need to be done sufficiently early to afford protection to these children before the 8 
winter peak in disease to maximise the benefit from immunisation. 9 
 10 
Conclusions 11 
Based on the criteria currently used by JCVI our models suggest only catch-up vaccination 12 
in 1 year old children could be recommended on economic grounds, incremental to the 13 
existing infant programme, but only if the vaccine could be procured at a low cost.  14 
  15 
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 1 
Table 1. Cost-effectiveness of catch-up vaccination assuming 88% vaccine strain coverage, 2 
30% vaccine efficacy against carriage acquisition and 95% vaccine efficacy against disease 3 
 Vaccine strategy Vaccination 
strategy 
compared 
with no 
vaccination 
Catch-up vaccination incremental on 
previous (row above) strategy* 
 
ICER at £75/ 
vaccine 
dose† 
ICER at £75/ 
vaccine 
dose† 
Vaccine 
price at 
£30k/ 
QALY‡ 
Vaccine 
price at 
£20k/ 
QALY‡  
3.5% discounting for costs and benefits 
2,4+12 months £168,000 - - - 
2,4+12 months + CU in 1y £167,400 £143,200 £13 £8 
2,4+12 months + CU in 1-2y £167,900 £199,800 £7 £3 
2,4+12 months + CU in 1-4y £170,100 £264,800 £2 NP 
1.5% discounting for costs and benefits 
2,4+12 months £114,200 - - - 
2,4+12 months + CU in 1y £113,600 £79,000 £29 £20 
2,4+12 months + CU in 1-2y £113,600 £111,000 £19 £12 
2,4+12 months + CU in 1-4y £114,100 £147,800 £12 £6 
*2,4+12 months + CU in 1y incremental on 2,4+12 months; 2,4+12 months + CU in 1-2y 
incremental on 2,4+12 months + CU in 1y etc. †Figures rounded to nearest 100. ‡Figures 
rounded to nearest £1. 
ICER, incremental cost-effectiveness ratio; QALY, Quality Adjusted Life Year; CU, catch-up 
vaccination; NP, positive vaccine price not possible. 
 4 
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 1 
Table 2. Cost-effectiveness of catch-up vaccination assuming 66% vaccine strain coverage, 2 
0% vaccine efficacy against carriage acquisition and 95% vaccine efficacy against disease 3 
 Vaccine strategy Vaccination 
strategy 
compared 
with no 
vaccination 
Catch-up vaccination incremental on 
previous (row above) strategy 
 
ICER at £75/ 
vaccine dose 
ICER at £75/ 
vaccine dose 
Vaccine 
price at 
£30k/ QALY 
Vaccine 
price at 
£20k/ QALY  
3.5% discounting for costs and benefits 
2,4+12 months £273,400 - - - 
2,4+12 months + CU in 1y £273,100 £262,700 £2 NP 
2,4+12 months + CU in 1-2y £274,800 £401,800 NP NP 
2,4+12 months + CU in 1-4y £280,300 £613,700 NP NP 
1.5% discounting for costs and benefits 
2,4+12 months £188,600 - - - 
2,4+12 months + CU in 1y £188,100 £151,100 £11 £6 
2,4+12 months + CU in 1-2y £188,500 £233,000 £4 NP 
2,4+12 months + CU in 1-4y £190,300 £358,300 NP NP 
*2,4+12 months + CU in 1y incremental on 2,4+12 months; 2,4+12 months + CU in 1-2y 
incremental on 2,4+12 months + CU in 1y etc. †Figures rounded to nearest 100. ‡Figures 
rounded to nearest £1. 
ICER, incremental cost-effectiveness ratio; QALY, Quality Adjusted Life Year; CU, catch-up 
vaccination; NP, positive vaccine price not possible. 
 4 
  5 
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